Nasdaq:US$19.89 (-0.20) | HKEX:HK$31.40 (-0.65) | AIM:£3.15 (-0.09)
Search Result
Previous Article   |   Next Article
Announcements & Press Releases | 8 Apr 2024

HMPL-506, a novel, highly potent and differentiated menin-MLL inhibitor for the treatment of MLL-rearranged and NPM1 mutant acute leukemia in preclinical models